DS BIOPHARMA LIMITED

Ds Biopharma Limited is a Dublin-based biopharmaceutical company dedicated to developing innovative topical therapies for dermatological conditions. The firm's core focus is on atopic dermatitis, where it has progressed a pipeline of novel agents from early-stage research through to clinical evaluation.

Among its flagship products is EPADILIN®, a proprietary compound that has attracted a strategic option and licence agreement with Nuvothera for development and commercialisation in the United States. In parallel, the company's 5 % DS107 cream has demonstrated, in a recent clinical study, the ability to prevent disease exacerbation in patients with atopic dermatitis, underscoring Ds Biopharma's commitment to delivering effective, patient-centred solutions. The company also contributes to scientific discourse, with abstracts accepted at the Atopic Dermatitis Centre of Reference and Excellence (ADCARE) conference.

Through collaborative partnerships, robust clinical programmes, and a clear focus on skin health, Ds Biopharma serves dermatologists and patients seeking advanced, evidence-based treatments for chronic skin disorders.